Other insomnia not due to a substance or known physiological condition
Methodology & AI Transparency ⓘ
Other insomnia not due to a substance or known physiological condition Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Other insomnia not due to a substance or known physiological condition (F51.09) in Sleep Disorders relies on airway pressure or in Other insomnia not due to a substance or known physiological condition (F51.09: orexin-targeted therapy evaluation), guiding step-wise therapeutic adjustments toward Apnea-Hypopnea Index (AHI) [Other insomnia not due to a substance or known physiological condition F51.09] (< 5 events/hour (F51.09)).
- 2 Real-world patient consensus: Clinical coding for Other insomnia not due to a substance or known physiological condition uses ICD-10 F51.09 across Sleep Disorders specialty care.
- 3 Typical cash cost range: Workup highlights for Other insomnia not due to a substance or known physiological condition (F51.09): airway pressure or in Other insomnia not due to a substance or known physiological condition (F51.09: orexin-targeted therapy evaluation).
- 4 Top reported side effects / signs: Objective lab/clinical target for Other insomnia not due to a substance or known physiological condition: Serum Ferritin (Restless in Other insomnia not due to a substance or known physiological condition (F51.09: Legs)) (> 75 ng/mL (F51.09)) and Apnea-Hypopnea Index (AHI) [Other insomnia not due to a substance or known physiological condition F51.09].
Ask our AI Specialists anything about Other insomnia not due to a substance or known physiological condition
What Is Other insomnia not due to a substance or known physiological condition?
Clinical triage of Other insomnia not due to a substance or known physiological condition (F51.09) in Sleep Disorders relies on airway pressure or in Other insomnia not due to a substance or known physiological condition (F51.09: orexin-targeted therapy evaluation), guiding step-wise therapeutic adjustments toward Apnea-Hypopnea Index (AHI) [Other insomnia not due to a substance or known physiological condition F51.09] (< 5 events/hour (F51.09)).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in sleep disorders, Other insomnia not due to a substance or known physiological condition (F51.09) involves fragmented slow-wave/REM sleep in Other insomnia not due to a substance or known physiological condition (F51.09: architecture). progression correlates with shifts in Serum Ferritin (Restless in Other insomnia not due to a substance or known physiological condition (F51.09: Legs)) (> 75 ng/mL (F51.09)).
Common Symptoms & Clinical Signs
- • Presentation of Other insomnia not due to a substance or known physiological condition (F51.09): daytime microsleeps, cognitive in Other insomnia not due to a substance or known physiological condition (F51.09: brain fog, or)
- • Secondary Other insomnia not due to a substance or known physiological condition clinical sign: prolonged sleep-onset latency [Other insomnia not due to a substance or known physiological condition F51.09]
- • Symptom flares in Other insomnia not due to a substance or known physiological condition correlating with Serum Ferritin (Restless in Other insomnia not due to a substance or known physiological condition (F51.09: Legs)) deviation outside > 75 ng/mL (F51.09)
- • Functional sleep disorders impact requiring airway pressure or in Other insomnia not due to a substance or known physiological condition (F51.09: orexin-targeted therapy evaluation) evaluation (F51.09)
Other insomnia not due to a substance or known physiological condition Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F51.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Other insomnia not due to a substance or known physiological condition (F51.09: Legs)) | > 75 ng/mL (F51.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Other insomnia not due to a substance or known physiological condition F51.09] | < 5 events/hour (F51.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Other insomnia not due to a substance or known physiological condition (F51.09: (ISI)) | < 7 (F51.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other insomnia not due to a substance or known physiological condition
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Hydroxocobalamin Cyanokit • RxCUI 700496 | Antidote | 89% | $0.8144 | $ 41.48 /mo |
| Nalmefene Hydrochloride Zurnai, Opvee • RxCUI 2720806 | Opioid Antagonist | 79% | $46.7362 | $ 185.00 /mo |
| Naloxone HCl Kloxxado, Rezenopy • RxCUI 2540703 | Opioid Antagonist | 92% | $59.7104 | $ 61.36 /mo |
| Akynzeo (Netupitant and Palonosetron) Akynzeo • RxCUI 1552349 | Substance P/Neurokinin-1 Receptor Antagonist | 82% | $3.4500 | $ 256.90 /mo |
| Cinvanti (Aprepitant) Cinvanti • RxCUI 1995155 | Substance P/Neurokinin-1 Receptor Antagonist | 83% | $164.4293 | $ 640.00 /mo |
| Fosnetupitant and Palonosetron Akynzeo • RxCUI RXN-69639105-3118 | Substance P/Neurokinin-1 Receptor Antagonist | 90% | $3.0900 | $ 133.64 /mo |
| Emend (Aprepitant) Emend • RxCUI 644088-B00060464 | Substance P/Neurokinin-1 Receptor Antagonist | 76% | $208.9830 | $ 599.92 /mo |
| Focinvez (Fosaprepitant Dimeglumine) Focinvez • RxCUI RXN-B82449231 | Substance P/Neurokinin-1 Receptor Antagonist | 80% | $3.0000 | $ 224.50 /mo |
| Varubi (Rolapitant) Varubi • RxCUI 1673373 | Substance P/Neurokinin-1 Receptor Antagonist | 92% | $0.5900 | $ 50.98 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other insomnia not due to a substance or known physiological condition)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other insomnia not due to a substance or known physiological condition Patient Community & “People Like Me” Threads
Filter Other insomnia not due to a substance or known physiological condition community threads and patient logs by age, biological sex, dosage, and treatment duration.